［Abstract］　With the progress of medical technology, more and more methods are used to treat lung cancer in clinic. Minimally invasive surgery and the hybridization of minimally invasive surgery and interventional therapy through multiple channels play an important role in the process of diagnosis and treatment. This paper illustrates the advantages and disadvantages of each channel and elaborates the hybridization of minimally invasive surgery and interventional therapy in the diagnosis and treatment of lung cancer.]]> 2022/4/29 9:03:57 LIU Jia-cong, ZHANG Yu-qian, WANG Xin, et al. 4true ［Abstract］　Venous thromboembolism(VTE) is a common complication in tumor patients, which seriously affects the prognosis and survival of the patients. The occurrence and development of VTE is influenced by many factors. Tumor progression and tumor treatment affect the count and function of numerous blood cells in the patients′ blood system, and the changes of the latter play an important role in tumor progression, promoting blood hypercoagulability and thrombosis. In addition to anticoagulant drugs targeting coagulation factors, drugs targeting corresponding targets of blood cells may become new approaches of VTE prevention and treatment in the future. Therefore, this paper reviews the research progress in blood cell count and functional changes, and tumor-associated VTE.]]> 2022/4/29 9:03:57 KE Li-hui, LI Hui 3true ［Abstract］　Cancer-associated venous thromboembolism(CAT) refers to malignant tumor complicated with venous thromboembolism, including deep vein thrombosis, superficial thrombophlebitis and pulmonary embolism. It is a common complication and cause of death in tumor patients. Tumor diseases are complex, and the risk of thrombosis and bleeding varies with tumor type, stage and disease progression.“Thrombosis-free ward” is a brand-new medical management mode. The inpatients are scored by using a venous thromboembolism risk assessment form and are divided into low-risk and high-risk patients according to the assessment results, and then appropriate interventions are carried out to better monitor the real-time embolism risk of the patients and prevent the occurrence of venous thromboembolism as soon as possible. Through the establishment of “thrombosis-free ward”, the medical staff can effectively improve the diagnosis and treatment level of thrombosis, and strengthen the awareness of the patients and their families about thrombosis. Based on the clinical practice of “thrombosis-free ward” in the radiotherapy department of our hospital, this paper reviews the current situation, risk assessment and prevention strategies of CAT.]]> 2022/4/29 9:03:57 HUANG Yun-xia, KANG Ya-jing, LIN Hui-juan, et al. 2true ［Abstract］　Objective　To investigate the therapeutic effect of dendritic cell-cytokine-induced killer cells(DC-CIK) immunotherapy combined with chemotherapy on patients with advanced lung cancer, and to analyze the changes of tumor markers, immune function indicators, serum miR-137 and miR-155 levels. Methods　Eighty-three patients with advanced lung cancer who were admitted to Suzhou Hospital Affiliated to Nanjing Medical University from January 2020 to January 2021 were selected and divided into the combination group(receiving DC-CIK immunotherapy combined with chemotherapy, 40 cases) and the chemotherapy group(receiving chemotherapy alone, 43 cases) according to their treatment intentions. The clinical efficacy, survival prognosis, tumor markers［carcinoembryonic antigen(CEA), cytokeratin 19 fragment(Cyfra21-1)］, immune function indicators［CD3⁺ T cells, CD4⁺ T cells, natural killer(NK) cells］, and serum miR-137 and miR-155 levels before and after treatment were compared between the two groups. Results　The objective response rate(ORR) and disease control rate(DCR) of the combination group were higher than those of the chemotherapy group, but the differences were not statistically significant(25.00% vs 18.60%, 75.00% vs 60.47%; P>0.05). After treatment, the levels of CEA, Cyfra21-1, miR-137 and miR-155 in the two groups were significantly lower than those before treatment(P<0.05), and the levels in the combination group were lower than those in the chemotherapy group, and the differences were statistically significant(P<0.05). After treatment, the levels of CD3⁺ T cells, CD4⁺ T cells and NK cells in the combination group were significantly higher than those before treatment(P<0.05), while the changes in the immune function indicators of the chemotherapy group were not significantly different(P>0.05). The levels of immune function indicators in the combination group were higher than those in the chemotherapy group, and the differences were statistically significant(P<0.05). The progression-free survival(PFS) and overall survival(OS) of the combination group were better than those of the chemotherapy group(P<0.05). Conclusion　Compared with chemotherapy alone, DC-CIK immunotherapy combined with chemotherapy can reduce the levels of tumor markers CEA and Cyfra21-1 and the levels of serum miR-137 and miR-155 in patients with advanced lung cancer, improve their immune function and prolong their survival.]]> 2022/4/29 9:03:57 HU Bo-wen, DU Ling-yu, YANG Yong 1true